Showing posts with label Gene Therapy Market. Show all posts
Showing posts with label Gene Therapy Market. Show all posts

In Vivo vs. Ex Vivo Gene Therapy: Which One Is Best?

Human gene therapy aims to change a gene's expression or the biological makeup of live cells for therapeutic purposes. Gene therapy is a method for treating or curing disease by changing a person's DNA. Gene treatments can function in a variety of ways:

Utilizing a healthy set of genes to replace a disease-causing gene

A disease-causing gene that is malfunctioning can be turned off.

The process of adding a new or altered gene to the organism to treat a condition

Products utilizing gene therapy are being investigated to treat diseases such as cancer, genetic disorders, and infectious diseases.


Gene therapy is now a field that primarily exists in research labs, and its applicability is still being tested. Most trials occur in the U.S., Europe, and Australia. The therapy options are varied and might include viral infections, acquired genetic illnesses including cancer, and diseases brought on by recessive gene defects.

Recombinant DNA technology is one of the most frequently used techniques. In this method, a healthy gene or gene of interest is inserted into a vector, which can be nanostructured, plasmidial, or viral; the latter is most frequently used because it is most effective at invading cells and introducing its genetic material.

What Is the Purpose of Gene Therapy?

Gene therapy aims to repair any harm brought on by any defective genes you may have. Gene therapy is ideally a means of treating or curing certain illnesses. Some people are born with faulty or missing genes. Some people have genes that evolve or alter with time.

New genes are introduced to replace or overcome the disease-causing, faulty genes already present in the body. Thus, the gene therapy market is predicted to grow in the coming years.

What Distinguishes In Vivo Gene Therapy from Ex Vivo Gene Therapy?

Ex-vivo gene therapy involves removing specific cells from the body and sending them to a lab. These cells are changed in the laboratory. A viral vector is frequently used to introduce fresh DNA into the cells. The freshly modified cells are then processed and returned to you, often by an intravenous infusion.

In-vivo gene therapy involves inserting fresh genetic material—typically DNA—directly into your cells. Typically, a vector delivers the novel genetic material straight to the target organ or by an injection into the blood. The in vivo gene therapy is expected to dominate the gene therapy market in the future.

Why Is Gene Therapy Delivered by Viruses?

A researcher may seek to utilize gene therapy to cure a genetic abnormality, and viruses offer a perfect method for delivering the therapy to the host cell. A virus is particularly successful at entering a cell because of its natural architecture.

Many viruses have had their whole genomes—the entire collection of genes that make up an organism—mapped or generated as blueprints by scientists. They can separate the viral genome's elements that are efficient at entering cells from the virus genome's potential pathogenic components. The gene therapy market is expected to increase faster in the virus category.

In addition, only a few harmless components of the original virus design are utilized, and these components are insufficient to spread a virus. Additionally, viral vectors are frequently used worldwide since they are more effective than non-viral alternatives. 


Share:

How is Rising Number of Cancer Cases Driving Gene Therapy Market?

The burden of chronic diseases has only been increasing since past few years. The cases for cancer, for example, are growing rapidly. According to the American Cancer Society, from 2016–2019, the number of new cases of cancer in the U.S. increased from 1,685,210 to 1,762,450, and the cancer mortality rose from 595,690 to 606,880 during the same time period. Doubtless, a number of advancements have been made in the medical industry for developing a proper cure for cancer and other rare chronic diseases, however, the fact remains that there is a long way to go before anything certain comes to light.

The advancements regarding gene therapy though can significantly aid in getting closer to dealing properly with several chronic diseases. Gene therapy is designed for introducing genetic material into cells for compensating for abnormal genes or for making a beneficial protein. In case a mutated gene causes an essential protein to be faulty or non-existent, gene therapy may potentially be able to introducing a new copy of the gene for restoring the function of the protein. Attributed to these reasons, the gene therapy market generated revenue of $3,407.5 million in 2019 and is expected to advance at a 31.1% CAGR during the forecast period (2020–2030).

To Learn More About this report: https://bit.ly/3doafIc

In 2019, North America was the largest gene therapy market, which is ascribed to the rising number of cancer and rare disease cases and the presence of a large number of key companies in the region. In addition to this, various gene therapy products are getting regulatory approvals in North America. Other than this, the adoption of gene therapy is also projected to rise substantially in the Asia-Pacific because of the cost-effective labor and rising activities of major industry players.

Hence, the requirement for gene therapy is growing due to the surging prevalence of chronic diseases.


Report Coverage
·         Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis

·         Porter analysis identifies competitive forces within the market
·         Provides information on the historical and current market size and the future potential of the market
·         Provides sizes of key regional markets using yardsticks of segments
Share:

Popular Posts

Blog Archive